UBS reduces DocMorris price target to 25 francs maintains sell rating

UBS has revised its price target for DocMorris, lowering it to 25 francs, while maintaining a "Sell" rating.

Concerns have been raised by analyst Sebastian Vogel about the online pharmacy's growth prospects in the German prescription drug market, indicating a weaker business outlook in the short term.

The report, published on October 16, 2024, reflects UBS's assessment of the current market conditions affecting DocMorris.

The stock's performance has been closely monitored, with recent trading data showing fluctuations in its value.

Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings